Trevi Therapeutics, Inc. TRVI Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Trevi Therapeutics, Inc. (TRVI) reported accretion (amortization) of discounts and premiums, investments of $431K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Trevi Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments increased by 9.1% year-over-year, from $395K to $431K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 2 years (2023 to 2025), Trevi Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a -12.2% compound annual growth rate (CAGR), from $2.13M to $1.64M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- The adjustment to the carrying value of investment securities to account for the difference between the purchase price and the face value over the life of the instrument. This reflects the non-cash income or expense recognized as investments approach maturity. It helps investors understand the effective yield of the company's treasury and investment portfolio.